BRPI0506496B8 - composição farmacêutica com tolerância melhorada no local de injeção compreendendo sulfobutiléter-ß-ciclodextrina e seu uso no tratamento de êmese composição farmacêutica com tolerância melhorada no local de injeção compreendendo sulfobutiléter-ß-ciclodextrina e seu uso no tratamento de êmese composição farmacêutica com tolerância melhorada no local de injeção compreendendo sulfobutiléter-ß-ciclodextrina e seu uso no tratamento de êmese - Google Patents
composição farmacêutica com tolerância melhorada no local de injeção compreendendo sulfobutiléter-ß-ciclodextrina e seu uso no tratamento de êmese composição farmacêutica com tolerância melhorada no local de injeção compreendendo sulfobutiléter-ß-ciclodextrina e seu uso no tratamento de êmese composição farmacêutica com tolerância melhorada no local de injeção compreendendo sulfobutiléter-ß-ciclodextrina e seu uso no tratamento de êmeseInfo
- Publication number
- BRPI0506496B8 BRPI0506496B8 BRPI0506496A BRPI0506496A BRPI0506496B8 BR PI0506496 B8 BRPI0506496 B8 BR PI0506496B8 BR PI0506496 A BRPI0506496 A BR PI0506496A BR PI0506496 A BRPI0506496 A BR PI0506496A BR PI0506496 B8 BRPI0506496 B8 BR PI0506496B8
- Authority
- BR
- Brazil
- Prior art keywords
- injection site
- cyclodextrin
- sulfobutylether
- emesis
- treatment
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 6
- 238000002347 injection Methods 0.000 title 4
- 239000007924 injection Substances 0.000 title 4
- 206010047700 Vomiting Diseases 0.000 title 3
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 title 3
- 229920000858 Cyclodextrin Polymers 0.000 abstract 4
- 239000003755 preservative agent Substances 0.000 abstract 4
- 230000002335 preservative effect Effects 0.000 abstract 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 abstract 3
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000000845 anti-microbial effect Effects 0.000 abstract 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 1
- 239000008297 liquid dosage form Substances 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Nanotechnology (AREA)
- Inorganic Chemistry (AREA)
- Medical Informatics (AREA)
- Oncology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Crystallography & Structural Chemistry (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54089704P | 2004-01-30 | 2004-01-30 | |
| PCT/IB2005/000100 WO2005082416A2 (en) | 2004-01-30 | 2005-01-17 | Antimicrobial preservatives to achieve multi-dose formulation using beta-cyclodextrins for liquid dosage forms |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| BRPI0506496A BRPI0506496A (pt) | 2007-02-13 |
| BRPI0506496A8 BRPI0506496A8 (pt) | 2017-11-14 |
| BRPI0506496B1 BRPI0506496B1 (pt) | 2018-10-09 |
| BRPI0506496B8 true BRPI0506496B8 (pt) | 2022-09-20 |
Family
ID=34910697
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0506496A BRPI0506496B8 (pt) | 2004-01-30 | 2005-01-17 | composição farmacêutica com tolerância melhorada no local de injeção compreendendo sulfobutiléter-ß-ciclodextrina e seu uso no tratamento de êmese composição farmacêutica com tolerância melhorada no local de injeção compreendendo sulfobutiléter-ß-ciclodextrina e seu uso no tratamento de êmese composição farmacêutica com tolerância melhorada no local de injeção compreendendo sulfobutiléter-ß-ciclodextrina e seu uso no tratamento de êmese |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US8183230B2 (https=) |
| EP (1) | EP1713504B1 (https=) |
| JP (1) | JP5021318B2 (https=) |
| KR (1) | KR100834232B1 (https=) |
| CN (1) | CN101090735A (https=) |
| AR (2) | AR047469A1 (https=) |
| AU (1) | AU2005216709B2 (https=) |
| BR (1) | BRPI0506496B8 (https=) |
| CA (1) | CA2554346C (https=) |
| CO (1) | CO5700794A2 (https=) |
| CY (1) | CY1119188T1 (https=) |
| DK (1) | DK1713504T3 (https=) |
| ES (1) | ES2638113T3 (https=) |
| HU (1) | HUE034099T2 (https=) |
| IL (1) | IL176676A0 (https=) |
| LT (1) | LT1713504T (https=) |
| NO (1) | NO20063858L (https=) |
| NZ (1) | NZ548236A (https=) |
| PL (1) | PL1713504T3 (https=) |
| PT (1) | PT1713504T (https=) |
| RU (1) | RU2332997C2 (https=) |
| SI (1) | SI1713504T1 (https=) |
| TW (1) | TW200524632A (https=) |
| WO (1) | WO2005082416A2 (https=) |
| ZA (1) | ZA200605148B (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201401597TA (en) | 2011-11-29 | 2014-05-29 | Jurox Pty Ltd | Methods of preserving injectable pharmaceutical compositions comprising a cyclodextrin and a hydrophobic drug |
| AU2013273764B2 (en) * | 2011-11-29 | 2016-05-05 | Zoetis Services Llc | Pharmaceutical compositions |
| HUE054186T2 (hu) * | 2013-07-19 | 2021-08-30 | Boehringer Ingelheim Vetmedica Gmbh | Éterezett ciklodextrin-származékokat tartalmazó, tartósított, folyékony, vizes gyógyászati készítmény |
| ES2883448T3 (es) | 2013-12-04 | 2021-12-07 | Boehringer Ingelheim Vetmedica Gmbh | Composiciones farmacéuticas mejoradas de pimobendán |
| NL2015865B1 (en) | 2015-11-27 | 2017-06-13 | Le Vet B V | Maropitant Formulation. |
| IL312486B2 (en) | 2017-04-10 | 2025-05-01 | Chase Therapeutics Corp | NK1 antagonist combination and method for treating synucleinopathies |
| CA3104811C (en) | 2017-06-30 | 2024-05-28 | Chase Therapeutics Corporation | Composition comprising pramipexole and nk1-antagonists for treating depression |
| EP3923916A4 (en) * | 2019-02-15 | 2022-12-21 | Saol International Development Ltd. | INJECTABLE PHENOL FORMULATIONS AND METHODS OF USE |
| EP3725298A1 (en) | 2019-04-16 | 2020-10-21 | Faes Farma, S.A. | Stable and preserved pharmaceutical compositions of bilastine |
| CN112370451A (zh) * | 2020-12-08 | 2021-02-19 | 河北科技大学 | 一种枸橼酸马罗匹坦包合物、注射液及制备方法 |
| AT527172A1 (de) | 2023-04-25 | 2024-11-15 | Vetviva Richter Gmbh | Maropitantformulierung |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5910510A (ja) * | 1982-07-08 | 1984-01-20 | Nippon Zenyaku Kogyo Kk | 低刺激性チアムリン注射剤 |
| JPS59152320A (ja) * | 1983-02-17 | 1984-08-31 | Takeda Chem Ind Ltd | 水性製剤 |
| JPS6419737A (en) * | 1987-07-15 | 1989-01-23 | Hitachi Ltd | Multilayer interconnection tape carrier |
| JPH039848A (ja) * | 1989-06-06 | 1991-01-17 | Canon Inc | 液体噴射記録装置 |
| UA27776C2 (uk) * | 1991-05-31 | 2000-10-16 | Пфайзер Інк. | Похідні хінуклідину та їх фармацевтично прийнятні солі, що є антагоністами речовини р у ссавців, фармацевтична композиція, що має антагоністичну дію на речовину р у ссавців |
| US5602112A (en) * | 1992-06-19 | 1997-02-11 | Supergen, Inc. | Pharmaceutical formulation |
| DK0668863T3 (da) * | 1992-11-12 | 1997-06-30 | Pfizer | Quinuclidinderivat som substans P-antagonist |
| US5393762A (en) * | 1993-06-04 | 1995-02-28 | Pfizer Inc. | Pharmaceutical agents for treatment of emesis |
| WO2000012137A1 (en) | 1998-09-02 | 2000-03-09 | Allergan Sales, Inc. | Preserved cyclodextrin-containing compositions |
| US6255320B1 (en) * | 1999-06-01 | 2001-07-03 | Pfizer Inc. | Polymorphs of a crystalline azo-bicyclo (2,2,2) octan-3-amine citrate and their pharmaceutical compositions |
| AU5975700A (en) | 1999-07-02 | 2001-01-22 | Janssen Pharmaceutica N.V. | Nasal formulation of an antifungal |
| US7163681B2 (en) * | 2000-08-07 | 2007-01-16 | Centocor, Inc. | Anti-integrin antibodies, compositions, methods and uses |
| US7034013B2 (en) | 2001-03-20 | 2006-04-25 | Cydex, Inc. | Formulations containing propofol and a sulfoalkyl ether cyclodextrin |
| EP1383445A4 (en) * | 2001-03-20 | 2005-04-13 | Cydex Inc | FORMULATIONS WITH PROPOFOL AND A SULFOALKYL ETHER CYCLODEXTRIN |
| SK252004A3 (sk) * | 2001-07-20 | 2005-03-04 | Pfizer Products Inc. | Použitie antagonistov receptora NK-1 na výrobu liečiva na liečenie abnormálneho úzkostného správania domácich zvierat a spôsob screeningu skúšanej zlúčeniny s cieľom stanoviť anxiolytickú účinnosť u psov |
| BR0307898A (pt) | 2002-02-22 | 2004-12-07 | Pharmacia Corp | Formulações de droga antibiótica oftálmica contendo um composto de ciclodextrina e cloreto de cetil piridìnio |
| US6869939B2 (en) | 2002-05-04 | 2005-03-22 | Cydex, Inc. | Formulations containing amiodarone and sulfoalkyl ether cyclodextrin |
| DE10228049A1 (de) | 2002-06-24 | 2004-01-15 | Merck Patent Gmbh | Flüssige Zubereitung enthaltend Oligopeptide |
| US6861526B2 (en) * | 2002-10-16 | 2005-03-01 | Pfizer Inc. | Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine |
| BRPI0507301A (pt) | 2004-01-30 | 2007-06-26 | Pfizer Prod Inc | composições farmacêuticas de antagonistas do receptor de nuerocinina e ciclodextrina e métodos para melhor toleráncia no local de injeção |
| MXPA06007964A (es) | 2004-01-30 | 2007-01-26 | Pfizer Prod Inc | Antagonistas del receptor nk-1 para mejorar la recuperacion de anestesia. |
| KR100812046B1 (ko) | 2004-02-02 | 2008-03-10 | 화이자 프로덕츠 인크. | 1-(2ｓ,3ｓ)-2-벤즈히드릴-ｎ-(5-삼급-부틸-2-메톡시벤질)퀴누클리딘-3-아민의 제조 방법 |
-
2005
- 2005-01-17 JP JP2006550330A patent/JP5021318B2/ja not_active Expired - Lifetime
- 2005-01-17 CN CNA2005800032849A patent/CN101090735A/zh active Pending
- 2005-01-17 PL PL05702263T patent/PL1713504T3/pl unknown
- 2005-01-17 PT PT57022634T patent/PT1713504T/pt unknown
- 2005-01-17 KR KR1020067015283A patent/KR100834232B1/ko not_active Expired - Lifetime
- 2005-01-17 CA CA002554346A patent/CA2554346C/en not_active Expired - Lifetime
- 2005-01-17 HU HUE05702263A patent/HUE034099T2/en unknown
- 2005-01-17 AU AU2005216709A patent/AU2005216709B2/en not_active Expired
- 2005-01-17 BR BRPI0506496A patent/BRPI0506496B8/pt active IP Right Grant
- 2005-01-17 LT LTEP05702263.4T patent/LT1713504T/lt unknown
- 2005-01-17 US US10/588,070 patent/US8183230B2/en active Active
- 2005-01-17 NZ NZ548236A patent/NZ548236A/en not_active IP Right Cessation
- 2005-01-17 SI SI200532166T patent/SI1713504T1/sl unknown
- 2005-01-17 EP EP05702263.4A patent/EP1713504B1/en not_active Expired - Lifetime
- 2005-01-17 RU RU2006127422/15A patent/RU2332997C2/ru not_active IP Right Cessation
- 2005-01-17 WO PCT/IB2005/000100 patent/WO2005082416A2/en not_active Ceased
- 2005-01-17 DK DK05702263.4T patent/DK1713504T3/en active
- 2005-01-17 ES ES05702263.4T patent/ES2638113T3/es not_active Expired - Lifetime
- 2005-01-27 AR ARP050100283A patent/AR047469A1/es not_active Application Discontinuation
- 2005-01-28 TW TW094102680A patent/TW200524632A/zh unknown
-
2006
- 2006-06-22 ZA ZA200605148A patent/ZA200605148B/en unknown
- 2006-07-03 IL IL176676A patent/IL176676A0/en unknown
- 2006-07-26 CO CO06073023A patent/CO5700794A2/es not_active Application Discontinuation
- 2006-08-29 NO NO20063858A patent/NO20063858L/no not_active Application Discontinuation
-
2017
- 2017-08-04 CY CY20171100843T patent/CY1119188T1/el unknown
- 2017-08-16 AR ARP170102291A patent/AR109357A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR109357A2 (es) | Composición farmacéutica parenteral con tolerancia en el sitio de inyección | |
| EP2305698A3 (en) | Macrocyclic inhibitors of Hepatitis C virus replication | |
| AR054064A1 (es) | Composicio con ingrediente farmaceutico activo en base a canabinoide para formas de dosis mejoradas | |
| BRPI0508540A (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BR0213522A (pt) | Composto, composição farmacêutica, métodos de inibir a hiv integrase e para prevenir ou tratar a infecção pelo hiv ou para prevenir, tratar ou retardar o inìcio da aids em um paciente, e, combinação útil para tratar ou prevenir a infecção pelo hiv ou para prevenir, tratar ou retardar o inìcio da aids | |
| US20100292199A1 (en) | Transcutaneous pharmaceutical compositions containing a steroid hormone | |
| BRPI0512985A (pt) | derivados de 3-carbamoil-2-piridona | |
| WO2007145991A3 (en) | Anti-inflammatory and analgesic compositions and related methods | |
| BRPI0415953B8 (pt) | formulação de dosagem de liberação controlada e conjunto de formas de dosagem de liberação controlada | |
| BRPI0914902B8 (pt) | Composição farmacêutica para uso no tratamento de mal de parkinson | |
| BRPI0508933A (pt) | composições para entrega tópica | |
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| JP6224165B2 (ja) | 抗真菌医薬組成物 | |
| BRPI0407506A (pt) | compostos para o tratamento de distúrbios metabólicos, seu uso e composição farmacêutica compreendendo os mesmos | |
| BRPI0508579A (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BRPI0714761B8 (pt) | formulações compreendendo compostos cíclicos | |
| AR074309A1 (es) | Compuestos anti-inflamatorios y sus composiciones farmaceuticas, dentifricas y adhesivas. metodo | |
| EA200401298A1 (ru) | Жидкие фармацевтические композиции, содержащие низкую дозу энтекавира, и их применение | |
| AR030957A1 (es) | Composiciones de analgesico y glucosamina | |
| NI202100031A (es) | Formulación basada en ciclodextrina de un inhibidor de bcl-2 | |
| MX2022006151A (es) | Derivados de 1,2,4-oxadiazol como agonistas del receptor hepatico x. | |
| AR063111A1 (es) | Una formulacion farmaceutica de taxano | |
| EP1790341A4 (en) | MEDICINE WITH ANALGESIC EFFECTS | |
| BRPI0515555A (pt) | composição farmacêutica compreendendo éster de temozolomida | |
| JP5743375B2 (ja) | カンジダ症予防又は治療剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: PAH USA 15 LLC (US) |
|
| B25D | Requested change of name of applicant approved |
Owner name: ZOETIS P LLC (US) |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: ZOETIS SERVICES LLC (US) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B25G | Requested change of headquarter approved |
Owner name: ZOETIS SERVICES LLC (US) |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Ipc: A61K 31/724 (2000.01), A61K 47/40 (1990.01), A61K |
|
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/10/2018, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/01/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B22E | Other requirements [chapter 22.5 patent gazette] |
Free format text: FORMULADA EXIGENCIA PARA ADEQUACAO OU CUMPRIMENTO DE DISPOSICOES LEGAIS NO PRAZO DE 60 (SESSENTA) DIAS DESTA DATA. |
|
| B16B | Notification of grant cancelled [chapter 16.2 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 16.3 NA RPI NO 2629 DE 25/05/2021 POR TER SIDO INDEVIDA. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: RETIFICACAO REF. RPI 2492, DE 09/10/2018. PRAZO DE VALIDADE: 10 ANOS CONTADOS A PARTIR DE 09/10/2018, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME A ADI 5.529/DF, COM APOSTILAMENTO DO PRAZO DE VALIDADE DA PROTECAO DA MATERIA RELATIVA A PRODUTOS E PROCESSOS FARMACEUTICOS E EQUIPAMENTOS E/OU MATERIAIS DE USO EM SAUDE, PARA APLICACAO EM HUMANOS. |